{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:17:48Z","timestamp":1784557068175,"version":"3.55.0"},"reference-count":10,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["edm.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1,1]]},"abstract":"\n Summary<\/jats:title>\n Hypercalcemia due to parathyroid carcinoma (PC) is safely and quickly controlled with rapidly increasing evocalcet doses. Most parathyroid carcinomas are detected because of hypercalcemia due to primary hyperparathyroidism (PHPT). Hypercalcemia becomes more severe in patients with PC than those with parathyroid adenoma or hyperplasia. Hypercalcemia often causes renal dysfunction, gastrointestinal symptoms, and psychiatric symptoms. Consequently, the serum calcium level needs to be promptly corrected. Here, we report a case of PC with remarkably persistent hypercalcemia, which we safely and quickly controlled with rapidly increasing evocalcet doses. A 77-year-old female presented with renal dysfunction. Her serum calcium (Ca) and intact parathyroid hormone serum levels were 13.9 mg\/dL and 1.074 pg\/mL, respectively. Her renal function worsened because of hypercalcemia due to PHPT. Technetium-99 m methoxy-isobutyl-isonitrile parathyroid scintigraphic examination revealed an accumulation below the right thyroid lobe. CT examination showed a 35-mm mass. Hypercalcemia needed to be immediately corrected because of the patient\u2019s worsening renal function. Evocalcet treatment at a gradually increasing dose of up to 20 mg over 3 weeks allowed her serum Ca level to be maintained below 11 mg\/dL. Only mild nausea was observed at the beginning of the treatment. The mass was suspected as PC because the hypercalcemia was refractory to high-dose evocalcet. The patient was treated with parathyroidectomy and ipsilateral thyroidectomy. PC was diagnosed based on the pathological findings of capsular and venous invasion. The patient\u2019s renal function improved and surgery could be safely performed by promptly correcting hypercalcemia.<\/jats:p>\n <\/jats:sec>\n \n Learning points<\/jats:title>\n \n \n Hypercalcemia due to parathyroid carcinoma (PC) is often more severe than that caused by parathyroid adenoma or hyperplasia.<\/jats:p>\n <\/jats:list-item>\n \n PC is a rare disease, but it should be considered if the patient has intractable hypercalcemia due to primary hyperparathyroidism (PHPT).<\/jats:p>\n <\/jats:list-item>\n \n Evocalcet, which is used to treat hypercalcemia due to PHPT, does not interact with P450 (CYP) and causes few side effects.<\/jats:p>\n <\/jats:list-item>\n \n Complications, including renal dysfunction, were improved and the surgery could be safely performed by promptly correcting hypercalcemia.<\/jats:p>\n <\/jats:list-item>\n \n \n PC has a high recurrence rate.\n En<\/jats:italic>\n -\n block<\/jats:italic>\n excision is necessary when PC is suspected.\n <\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:sec>","DOI":"10.1530\/edm-22-0269","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T12:40:22Z","timestamp":1672922422000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-2","source":"Crossref","is-referenced-by-count":0,"title":["Effect of early dose increase of evocalcet for intractable hypercalcemia caused by parathyroid carcinoma"],"prefix":"10.1530","volume":"2023","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0439-0881","authenticated-orcid":true,"given":"Azusa","family":"Morishita","sequence":"first","affiliation":[{"name":"Department of Nephrology, Yaizu City Hospital, Dobara, Yaizu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Hozumi","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgery, Ibaraki Prefectural Central Hospital, Koibuchi, Kasama, Ibaraki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Yaizu City Hospital, Dobara, Yaizu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Hokazono","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yaizu City Hospital, Dobara, Yaizu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clovis","family":"Manuel Yosei Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Yaizu City Hospital, Dobara, Yaizu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Shimasaki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Yaizu City Hospital, Dobara, Yaizu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Itaya","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Yaizu City Hospital, Dobara, Yaizu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Oura","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Yaizu City Hospital, Dobara, Yaizu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kuriki","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yaizu City Hospital, Dobara, Yaizu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Hishida","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Yaizu City Hospital, Dobara, Yaizu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Seki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Yaizu City Hospital, Dobara, Yaizu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Current Treatment Options in Oncology","first-page":"11","article-title":"Parathyroid carcinoma: update and guidelines for management","volume":"13","author":"Wei","year":"2012","unstructured":"Wei CHHarari A. Parathyroid carcinoma: update and guidelines for management. Current Treatment Options in Oncology20121311\u201323. (https:\/\/doi.org\/10.1007\/s11864-011-0171-3)"},{"key":"bib2","series-title":"Kidney International","first-page":"818","article-title":"Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism","volume":"94","author":"Fukagawa","year":"2018","unstructured":"Fukagawa MShimazaki RAkizawa T & Evocalcet study group. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney International201894818\u2013825. (https:\/\/doi.org\/10.1016\/j.kint.2018.05.013)"},{"key":"bib3","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"485","article-title":"Clinical review 122: Parathyroid carcinoma","volume":"86","author":"Shane","year":"2001","unstructured":"Shane EClinical review 122: Parathyroid carcinoma. Journal of Clinical Endocrinology and Metabolism200186485\u2013493. (https:\/\/doi.org\/10.1210\/jcem.86.2.7207)"},{"key":"bib4","series-title":"Journal of Bone and Mineral Metabolism","first-page":"687","article-title":"Evocalcet in patients with primary hyperparathyroidism: an open-label, single-arm, multicenter, 52-week, dose-titration phase III study","volume":"38","author":"Takeuchi","year":"2020","unstructured":"Takeuchi YNishida YKondo YImanishi YFukumoto S. Evocalcet in patients with primary hyperparathyroidism: an open-label, single-arm, multicenter, 52-week, dose-titration phase III study. Journal of Bone and Mineral Metabolism202038687\u2013694. (https:\/\/doi.org\/10.1007\/s00774-020-01097-y)"},{"key":"bib5","series-title":"Clinical Drug Investigation","first-page":"945","article-title":"Pharmacokinetics, pharmacodynamics, and safety of the novel calcimimetic agent evocalcet in healthy Japanese subjects: first-in-human phase I study","volume":"38","author":"Akizawa","year":"2018","unstructured":"Akizawa TShimazaki RShiramoto MFukagawa M & Evocalcet Study Group. Pharmacokinetics, pharmacodynamics, and safety of the novel calcimimetic agent evocalcet in healthy Japanese subjects: first-in-human phase I study. Clinical Drug Investigation201838945\u2013954. (https:\/\/doi.org\/10.1007\/s40261-018-0687-4)"},{"key":"bib6","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"3803","article-title":"Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma","volume":"92","author":"Silverberg","year":"2007","unstructured":"Silverberg SJRubin MRFaiman CPeacock MShoback DMSmallridge RCSchwanauer LEOlson KAKlassen PBilezikian JP. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. Journal of Clinical Endocrinology and Metabolism2007923803\u20133808. (https:\/\/doi.org\/10.1210\/jc.2007-0585)"},{"key":"bib7","series-title":"Endocrine","first-page":"283","article-title":"Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism","volume":"39","author":"Faggiano","year":"2011","unstructured":"Faggiano ADi Somma CRamundo VSeverino RVuolo LCoppola APanico FSavastano SLombardi GColao ACinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. Endocrine201139283\u2013287. (https:\/\/doi.org\/10.1007\/s12020-011-9459-0)"},{"key":"bib8","series-title":"Archives of Surgery","first-page":"878","article-title":"Localization and reoperation results for persistent and recurrent parathyroid carcinoma","volume":"136","author":"Kebebew","year":"2001","unstructured":"Kebebew EArici CDuh QYClark OH. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Archives of Surgery2001136878\u2013885. (https:\/\/doi.org\/10.1001\/archsurg.136.8.878)"},{"key":"bib9","series-title":"Surgery","first-page":"1423","article-title":"Risk factors for 30-day hospital readmission after thyroidectomy and parathyroidectomy in the United States: an analysis of National Surgical Quality Improvement Program outcomes","volume":"156","author":"Mullen","year":"2014","unstructured":"Mullen MGLaPar DJDaniel SKTurrentine FEHanks JBSmith PW. Risk factors for 30-day hospital readmission after thyroidectomy and parathyroidectomy in the United States: an analysis of National Surgical Quality Improvement Program outcomes. Surgery20141561423\u201330; discussion 1430. (https:\/\/doi.org\/10.1016\/j.surg.2014.08.074)"},{"key":"bib10","series-title":"Otolaryngology\u2013Head and Neck Surgery","first-page":"955","article-title":"Unplanned 30-day readmissions after parathyroidectomy in patients with chronic kidney disease: a nationwide analysis","volume":"157","author":"Ferrandino","year":"2017","unstructured":"Ferrandino RRoof SMa YChan LPoojary PSaha AChauhan KCoca SGNadkarni GNTeng MS. Unplanned 30-day readmissions after parathyroidectomy in patients with chronic kidney disease: a nationwide analysis. Otolaryngology\u2013Head and Neck Surgery2017157955\u2013965. (https:\/\/doi.org\/10.1177\/0194599817721154)"}],"container-title":["Endocrinology, Diabetes & Metabolism Case Reports"],"original-title":[],"link":[{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2023\/1\/EDM22-0269.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2023\/1\/EDM22-0269.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/edm.bioscientifica.com\/view\/journals\/edm\/2023\/1\/EDM22-0269.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:47:57Z","timestamp":1784555277000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/edm\/article\/3141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":10,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/edm-22-0269","relation":{},"ISSN":["2052-0573"],"issn-type":[{"value":"2052-0573","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,1]]}}}